유방암 액체 생검 검사 기기 시장 : 세계 예측(2026-2032년)

The Breast Cancer Liquid Biopsy Testing Devices Market is projected to grow by USD 2.44 billion at a CAGR of 8.41% by 2032.

Breast cancer liquid biopsy testing devices are becoming increasingly important in precision oncology by enabling minimally invasive detection and longitudinal monitoring of tumor-derived biomarkers in blood and other body fluids. These devices support analysis of circulating tumor DNA, circulating tumor cells, extracellular vesicles, microRNAs, methylation signatures, fragmentomic patterns, and protein-based markers, helping clinicians complement tissue biopsy when tumor access is limited, disease is heterogeneous, or repeated sampling is clinically necessary. In breast cancer care, liquid biopsy is especially relevant for identifying actionable genomic alterations, monitoring treatment response, detecting emerging resistance, and supporting therapy selection in advanced or metastatic disease. The field is being shaped by rapid progress in next-generation sequencing, digital PCR, microfluidics, automated sample preparation, high-sensitivity enrichment technologies, and bioinformatics platforms that improve analytical sensitivity and workflow reproducibility. Regulatory expectations, clinical validation requirements, data integrity standards, and reimbursement pathways remain central to adoption, as healthcare systems increasingly require evidence that liquid biopsy testing improves decision-making, patient outcomes, and resource utilization without replacing clinically necessary tissue pathology.

Transformative Shifts in the Breast Cancer Liquid Biopsy Landscape

The breast cancer liquid biopsy landscape is shifting from exploratory biomarker research toward clinically integrated diagnostic workflows. A key transformation is the move from single-marker assays to broader multi-analyte and multi-gene approaches capable of capturing tumor heterogeneity across metastatic sites and tracking resistance mechanisms such as endocrine therapy escape and targeted therapy resistance. Devices are also evolving from highly manual centralized laboratory instruments toward more automated, standardized, and potentially decentralized testing platforms that reduce turnaround time and sample handling variability. Clinical use is expanding beyond mutation detection to include measurable residual disease research, therapy resistance surveillance, molecular relapse monitoring, and real-time disease monitoring, although implementation depends on robust evidence and alignment with clinical guidelines. Another major shift is the growing emphasis on pre-analytical quality, including blood collection tube performance, plasma separation protocols, nucleic acid preservation, hemolysis assessment, leukocyte contamination control, and chain-of-custody procedures, as these factors directly influence test reliability. Interoperability with electronic health records, molecular tumor boards, laboratory information systems, and clinical decision support systems is further transforming liquid biopsy from a standalone test into a connected precision medicine tool.

Cumulative Impact of Artificial Intelligence on Liquid Biopsy Testing

Artificial intelligence is accelerating the development and clinical utility of breast cancer liquid biopsy testing devices by improving signal detection, variant interpretation, assay optimization, and workflow automation. AI-enabled bioinformatics can help distinguish low-frequency tumor-derived variants from sequencing noise, clonal hematopoiesis, germline background, and technical artifacts, which is essential for high-sensitivity applications such as recurrence monitoring and low-burden disease assessment. Machine learning models are also being used to integrate genomic, fragmentomic, epigenomic, proteomic, imaging, pathology, treatment history, and clinical data to support more comprehensive cancer profiling. In device development, AI can optimize microfluidic capture, image-based circulating tumor cell detection, digital pathology correlation, laboratory quality control, and throughput management. However, the cumulative impact of AI depends on transparent validation, representative training datasets, bias mitigation, explainability, cybersecurity, auditability, and regulatory-grade documentation. For clinical adoption, AI-driven liquid biopsy systems must demonstrate reproducibility across populations, specimen types, instruments, sequencing chemistries, and laboratory environments while maintaining clinician trust and compliance with data protection standards.

Key Regional Insights Across Asia-Pacific, Europe, North America, Latin America, Africa, and Middle East

Asia-Pacific is a high-priority region for breast cancer liquid biopsy testing devices due to rising cancer screening activity, expanding oncology infrastructure, and increasing use of molecular diagnostics in countries such as China, India, Japan, South Korea, and Australia. The region shows strong demand for scalable testing workflows that can address diverse healthcare settings, from advanced urban cancer centers to resource-constrained facilities, while public health authorities continue to emphasize earlier cancer detection and improved access to pathology services. Europe demonstrates strong momentum through guideline-driven oncology care, cross-border research collaboration, national cancer plans, and regulatory emphasis on diagnostic quality, data protection, clinical evidence, and in vitro diagnostic performance. North America remains a leading environment for clinical implementation because of mature precision oncology networks, established molecular pathology capacity, active clinical trial ecosystems, structured regulatory oversight, and broad integration of genomic profiling in advanced cancer care. In Latin America, adoption is progressing through private oncology networks, academic cancer centers, and regional efforts to improve access to advanced diagnostics, although affordability, out-of-pocket exposure, reimbursement variability, and uneven laboratory infrastructure remain important barriers. Africa presents a more uneven adoption profile, with opportunities linked to centralized reference laboratories, international research partnerships, and efforts to expand cancer diagnostic access, while constraints include infrastructure gaps, workforce shortages, late-stage diagnosis, and cost sensitivity. The Middle East is investing in oncology modernization, genomic medicine programs, tertiary care infrastructure, and national health transformation initiatives, supporting selective adoption of liquid biopsy in advanced breast cancer management where specialist oncology services and molecular laboratories are available.

Key Group Insights Across NATO, G7, BRICS, European Union, ASEAN, and GCC

NATO member countries include many advanced healthcare systems with demand for interoperable, secure, and resilient diagnostic technologies, particularly where precision oncology is embedded in national cancer control strategies and where cybersecurity, continuity of care, and protected health data exchange are high priorities. G7 countries generally support faster integration of breast cancer liquid biopsy testing devices through established clinical research networks, specialist oncology centers, mature molecular pathology infrastructure, and advanced reimbursement discussions, though evidence thresholds for clinical utility, analytical validity, and cost-effectiveness remain rigorous. BRICS economies represent a diverse opportunity base, combining large patient populations, expanding oncology infrastructure, increasing domestic interest in molecular diagnostics, and policy attention to cancer care access, but adoption is shaped by pricing pressure, regulatory differences, local manufacturing priorities, and unequal access between urban and rural settings. The European Union offers a structured environment for adoption through harmonized in vitro diagnostic regulation, strong public health systems, cross-border research programs, and emphasis on evidence-based diagnostics, while implementation varies by reimbursement policy, national molecular testing capacity, and regional laboratory networks. ASEAN countries are increasingly relevant as healthcare systems expand cancer diagnostics, regional laboratory capacity, and specialist oncology services, with adoption most visible in higher-capacity markets and private specialty care. The GCC benefits from government-backed healthcare transformation, growing genomic medicine initiatives, digital health investment, and advanced oncology service development, creating demand for high-quality liquid biopsy workflows that align with international clinical standards and accredited laboratory practice.

Key Country Insights for Breast Cancer Liquid Biopsy Testing Devices

China is rapidly expanding cancer genomics, hospital-based molecular diagnostics, clinical oncology research, and domestic device development, supporting broad interest in liquid biopsy technologies for breast cancer management. The United States is a major adopter of breast cancer liquid biopsy testing devices due to advanced oncology care pathways, broad clinical trial activity, established molecular profiling in metastatic disease, and active regulatory engagement around high-complexity diagnostics. Japan's adoption is supported by advanced healthcare infrastructure, precision medicine policy, high diagnostic quality standards, and strong integration of molecular testing into specialist oncology care. India presents strong long-term potential due to high disease burden, expanding private healthcare, growing molecular laboratory networks, and demand for cost-effective testing suited to varied care settings. Germany has strong diagnostic laboratory expertise, oncology research capacity, and regulatory rigor, while the United Kingdom supports molecular testing through national cancer strategies and centralized genomics services, creating a structured pathway for clinically validated liquid biopsy use. Australia benefits from strong cancer registries, academic research, molecular pathology expertise, and national attention to equitable access across geographically dispersed populations, while France emphasizes validated precision medicine integration through cancer networks and clinical programs. South Korea combines advanced digital health infrastructure, strong biotechnology capabilities, and high clinical interest in precision oncology, supporting adoption in tertiary hospitals and research-oriented cancer centers. Italy and Spain are advancing molecular oncology adoption through specialist hospitals and research networks, with reimbursement and regional healthcare differences influencing implementation. Canada emphasizes evidence-based integration through provincial healthcare systems and cancer agencies, with access shaped by reimbursement and laboratory capacity. Russia has expanding oncology modernization initiatives, although access, regional healthcare variation, and international technology availability can differ. Brazil leads much of Latin America in specialized oncology infrastructure, with liquid biopsy adoption concentrated in major urban centers, while Mexico is seeing growing use in private oncology and reference laboratory settings, supported by demand for less invasive diagnostics but constrained by cost variability.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated device performance, including sensitivity, specificity, limit of detection, reproducibility, precision, interference assessment, sample stability, and concordance with tissue-based testing where appropriate. Investment should focus on robust pre-analytical systems, standardized workflows, and automated sample-to-result platforms that reduce variability and support scalable implementation. Developers should design assays around clinically actionable breast cancer biomarkers, treatment resistance mechanisms, molecular subtype relevance, and longitudinal monitoring use cases that align with oncology guidelines and real-world clinical needs. Evidence generation should include prospective clinical studies, diverse patient populations, real-world performance evaluation, health economic assessment, and clear demonstration of clinical utility. Partnerships with hospitals, molecular pathology laboratories, biobanks, academic oncology networks, and cancer registries can accelerate validation and adoption. Leaders should also strengthen regulatory readiness, cybersecurity, data governance, AI transparency, post-market performance monitoring, and quality management for software-enabled devices. To improve access, organizations should consider tiered testing models, regional reference laboratory strategies, training programs, clinician education, and workflows that fit both high-resource and emerging healthcare settings.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources relevant to breast cancer liquid biopsy testing devices. The methodology includes review of peer-reviewed oncology and molecular diagnostics literature, clinical practice guidelines, regulatory agency publications, public health resources, cancer control documentation, in vitro diagnostic standards, technology assessment materials, and published evidence on precision oncology implementation. Emphasis is placed on clinically established biomarker categories, validated testing technologies, regulatory considerations, pre-analytical and analytical quality requirements, and documented adoption factors across regions, groups, and countries. Insights are synthesized through triangulation across scientific evidence, healthcare infrastructure indicators, diagnostic workflow requirements, clinical guideline alignment, and precision oncology implementation trends. The analysis excludes speculative market sizing, market share, and forecasting. Findings are framed to support strategic understanding of technology adoption, clinical utility, regional readiness, operational priorities, and evidence requirements while maintaining consistency with evidence-based healthcare and diagnostic device evaluation standards.

Conclusion

Breast cancer liquid biopsy testing devices are reshaping precision oncology by enabling minimally invasive, repeatable, and biomarker-driven assessment of disease status, tumor evolution, and therapeutic resistance. Their clinical value is strongest when integrated into validated care pathways, supported by high-quality sample handling, analytically robust platforms, clinically actionable reporting, and multidisciplinary interpretation. Artificial intelligence, automation, multi-analyte testing, and connected clinical decision systems are expected to further improve diagnostic performance and workflow efficiency, provided they meet rigorous standards for transparency, validation, quality control, and regulatory compliance. Regional adoption will remain influenced by healthcare infrastructure, reimbursement, laboratory capacity, clinician education, data governance, and access to advanced oncology services. Industry participants that focus on evidence generation, operational standardization, affordability, and global adaptability will be best positioned to support broader clinical use of liquid biopsy in breast cancer care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Breast Cancer Liquid Biopsy Testing Devices Market, by Technology

• 7.1. Introduction
• 7.2. Digital PCR
  • 7.2.1. Chip Based Digital PCR
  • 7.2.2. Droplet Digital PCR
• 7.3. Next Generation Sequencing
  • 7.3.1. Targeted Sequencing
  • 7.3.2. Whole Exome Sequencing
  • 7.3.3. Whole Genome Sequencing
• 7.4. Real Time PCR
  • 7.4.1. Dye Based PCR
  • 7.4.2. Probe Based PCR

8. Breast Cancer Liquid Biopsy Testing Devices Market, by Test Type

• 8.1. Introduction
• 8.2. In Vitro Diagnostic
  • 8.2.1. Instruments
  • 8.2.2. Reagents
• 8.3. Laboratory Developed Test

9. Breast Cancer Liquid Biopsy Testing Devices Market, by Sample Type

• 9.1. Introduction
• 9.2. Plasma
• 9.3. Serum
• 9.4. Whole Blood

10. Breast Cancer Liquid Biopsy Testing Devices Market, by Indication

• 10.1. Introduction
• 10.2. Early Detection
• 10.3. Prognosis
• 10.4. Recurrence Detection
• 10.5. Treatment Monitoring

11. Breast Cancer Liquid Biopsy Testing Devices Market, by Application

• 11.1. Introduction
• 11.2. Circulating Tumor Cells
• 11.3. Circulating Tumor DNA
• 11.4. Exosomes

12. Breast Cancer Liquid Biopsy Testing Devices Market, by End User

• 12.1. Introduction
• 12.2. Contract Research Organizations
• 12.3. Diagnostic Laboratories
• 12.4. Hospitals And Clinics
• 12.5. Research Centers

13. Breast Cancer Liquid Biopsy Testing Devices Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Breast Cancer Liquid Biopsy Testing Devices Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Breast Cancer Liquid Biopsy Testing Devices Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Agena Bioscience, Inc.
• 17.2. ANGLE plc
• 17.3. Bio-Rad Laboratories, Inc.
• 17.4. Biocept, Inc.
• 17.5. Burning Rock Biotech Limited
• 17.6. Canexia Health Inc.
• 17.7. Cynvenio Biosystems, Inc.
• 17.8. Exact Sciences Corporation
• 17.9. F. Hoffmann-La Roche Ltd
• 17.10. Foundation Medicine, Inc.
• 17.11. Freenome Holdings, Inc.
• 17.12. GRAIL, LLC
• 17.13. Guardant Health, Inc.
• 17.14. Illumina, Inc.
• 17.15. Lucence Health Inc.
• 17.16. Menarini Silicon Biosystems S.p.A.
• 17.17. Myriad Genetics, Inc.
• 17.18. Natera, Inc.
• 17.19. NeoGenomics, Inc.
• 17.20. OncoCyte Corporation
• 17.21. Personalis, Inc.
• 17.22. Predicine, Inc.
• 17.23. QIAGEN N.V.
• 17.24. SeekIn Inc.
• 17.25. Sysmex Corporation
• 17.26. Thermo Fisher Scientific Inc.